Clinical Trials on Growth Retardation in Hong Kong

Total 14 results

Chinese University of Hong Kong

Recruiting

Thumb Ossification Composite Index (TOCI) to Predict Skeletal Maturity and Curve Progression in AIS (TOCI)

Bone Diseases | Scoliosis; Adolescence | Bone Growth Abnormal

Hong Kong
Eunice Kennedy Shriver National Institute of Child...

Completed

The NICHD Fetal Growth Study: Twin Gestations

Fetal Growth Restriction | Growth Discordancy

United States
Obstetrix Medical Group

Terminated

Amniotic Fluid Tandem Mass Spectrometry for Pregnancies Complicated by NIH and Severe Symmetrical IUGR (TandemMS)

Fetal Growth Retardation | Hydrops Fetalis

United States
Insmed Incorporated

Completed

IGF-I/IGFBP-3 Therapy in Children and Adolescents With Growth Hormone Insenitivity Syndrome (GHIS) Such as Laron Syndrome

Laron Syndrome | Growth Hormone Insensitivity Syndrome (GHIS)

United States, Argentina, Australia, Brazil, China, Egypt, Germany, Israel, Italy, Norway, Peru, Slovakia, Turkey, United Kingdom
Eunice Kennedy Shriver National Institute of Child...

Completed

The National Standard for Normal Fetal Growth

Pregnancy | Fetal Growth

United States
Green Cross Corporation

Completed

To Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients

Mucopolysaccharidosis II

Korea, Republic of
Taiho Oncology, Inc.

Recruiting

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation. (REZILIENT2)

Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

United States, Japan, Spain, Italy, France, Australia, Korea, Republic of, United Kingdom, Canada, Germany, Turkey, Hong Kong
Hoffmann-La Roche

Completed

A Study of RO4917523 in Pediatric Patients With Fragile X Syndrome

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Completed

Efficacy and Safety Study of STX209 (Arbaclofen) for Social Withdrawal in Adolescents and Adults With Fragile X Syndrome (Harbor-A)

Fragile X Syndrome

United States
Seaside Therapeutics, Inc.

Terminated

An Open Label Extension Study in Subjects With Fragile X Syndrome (209FX303)

Fragile X Syndrome

United States
Merck KGaA, Darmstadt, Germany

Completed

Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL) (CRYSTAL)

Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer

Sweden, Australia, Brazil, Bulgaria, France, Italy, Korea, Republic of, Russian Federation, South Africa, Spain, Turkey, United Kingdom, Germany, Hungary, Poland, Romania, Austria, Belgium, Finland, Netherlands, Slovakia, Greece, Ta... and more
Seaside Therapeutics, Inc.

Completed

Efficacy and Safety Study of STX209 (Arbaclofen) for the Treatment of Social Withdrawal in Children With Fragile X Syndrome (Harbor-C)

Fragile X Syndrome

United States
Hoffmann-La Roche

Completed

A Study of RO4917523 in Patients With Fragile X Syndrome

Fragile X Syndrome

France, Spain, United States, Peru, Canada, United Kingdom, Chile, Argentina, Mexico, Sweden
Daiichi Sankyo
Daiichi Sankyo Co., Ltd.

Active, not recruiting

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer Metastatic | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

United States, Spain, Korea, Republic of, France, United Kingdom, Taiwan, Australia, Japan, China, Netherlands, Italy, Germany, Austria, Belgium, Bulgaria, Singapore

Clinical Trials on Growth Retardation in Hong Kong

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Zimbabwe

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations